Martin Overseas

RYBELSUS® (semaglutide) tablets 3mg, 7 mg or 14 mg is a prescription medicine used along with diet and exercise to improve blood sugar (glucose) in adults with type 2 diabetes.

• It is not known if RYBELSUS® can be used in people who have had pancreatitis
• RYBELSUS® is not for use in people with type 1 diabetes
• It is not known if RYBELSUS® is safe and effective for use in children under 18 years of age

• Key takeaways:

  • Rybelsus (semaglutide) is an oral medication approved to treat Type 2 diabetes. It contains the same active ingredient as Ozempic and Wegovy. Ozempic is approved for Type 2 diabetes, and Wegovy is approved for chronic weight management.

  • Rybelsus is currently being studied for weight loss in clinical trials. These studies involve higher doses than what’s currently approved and available for diabetes. 

  • Results show that an oral semaglutide (Rybelsus) dose of 50 mg results in similar weight loss as Wegovy. Due to these findings, Rybelsus’ manufacturer plans to request FDA approval in 2023. If approved for weight loss, it may be marketed under a different brand name.

RYBELSUS® (semaglutide) tablets 3mg, 7 mg or 14 mg is a prescription medicine used along with diet and exercise to improve blood sugar (glucose) in adults with type 2 diabetes.

• It is not known if RYBELSUS® can be used in people who have had pancreatitis
• RYBELSUS® is not for use in people with type 1 diabetes
• It is not known if RYBELSUS® is safe and effective for use in children under 18 years of age

• Key takeaways:

  • Rybelsus (semaglutide) is an oral medication approved to treat Type 2 diabetes. It contains the same active ingredient as Ozempic and Wegovy. Ozempic is approved for Type 2 diabetes, and Wegovy is approved for chronic weight management.

  • Rybelsus is currently being studied for weight loss in clinical trials. These studies involve higher doses than what’s currently approved and available for diabetes. 

  • Results show that an oral semaglutide (Rybelsus) dose of 50 mg results in similar weight loss as Wegovy. Due to these findings, Rybelsus’ manufacturer plans to request FDA approval in 2023. If approved for weight loss, it may be marketed under a different brand name.

Mounjaro 5mg Solution for Injection is administered once weekly subcutaneously in the abdomen, thigh, or upper arm. To maximize its benefits, maintain a consistent injection schedule and complement treatment with a healthy diet and regular exercise. Follow your doctor’s instructions carefully, including any dose adjustments, and store the medication properly in the refrigerator.

Common side effects of Mounjaro 5mg Solution for Injection include nausea, diarrhea, vomiting, constipation, abdominal pain, and dyspepsia (indigestion). These symptoms are typically mild and improve over time. If they become severe or persistent, consult a doctor. They can help by adjusting the dose or suggesting ways to prevent them. Drinking plenty of water and staying hydrated may also help reduce discomfort from gastrointestinal symptoms.

Mounjaro 5mg Solution for Injection should not be used by individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2). Pregnant individuals or those planning to become pregnant should avoid this medicine as it may cause harmful effects on the developing baby. Before taking this medicine, inform your doctor about all the other medicines you are taking to avoid interaction.

• To improve glycemic control in adults with Type 2 diabetes mellitus
• Management of Obesity

RYBELSUS® (semaglutide) tablets 3mg, 7 mg or 14 mg is a prescription medicine used along with diet and exercise to improve blood sugar (glucose) in adults with type 2 diabetes.

• It is not known if RYBELSUS® can be used in people who have had pancreatitis
• RYBELSUS® is not for use in people with type 1 diabetes
• It is not known if RYBELSUS® is safe and effective for use in children under 18 years of age

• Key takeaways:

  • Rybelsus (semaglutide) is an oral medication approved to treat Type 2 diabetes. It contains the same active ingredient as Ozempic and Wegovy. Ozempic is approved for Type 2 diabetes, and Wegovy is approved for chronic weight management.

  • Rybelsus is currently being studied for weight loss in clinical trials. These studies involve higher doses than what’s currently approved and available for diabetes. 

  • Results show that an oral semaglutide (Rybelsus) dose of 50 mg results in similar weight loss as Wegovy. Due to these findings, Rybelsus’ manufacturer plans to request FDA approval in 2023. If approved for weight loss, it may be marketed under a different brand name.

Mounjaro 2.5mg Solution for Injection is administered once weekly subcutaneously in the abdomen, thigh, or upper arm. To maximize its benefits, maintain a consistent injection schedule and complement treatment with a healthy diet and regular exercise. Follow your doctor’s instructions carefully, including any dose adjustments, and store the medication properly in the refrigerator.

Common side effects of Mounjaro 2.5mg Solution for Injection include nausea, diarrhea, vomiting, constipation, abdominal pain, and dyspepsia (indigestion). These symptoms are typically mild and improve over time. If they become severe or persistent, consult a doctor. They can help by adjusting the dose or suggesting ways to prevent them. Drinking plenty of water and staying hydrated may also help reduce discomfort from gastrointestinal symptoms.

Mounjaro 2.5mg Solution for Injection should not be used by individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2). Pregnant individuals or those planning to become pregnant should avoid this medicine as it may cause harmful effects on the developing baby. Before taking this medicine, inform your doctor about all the other medicines you are taking to avoid interaction.

• To improve glycemic control in adults with Type 2 diabetes mellitus
• Management of Obesity

RYBELSUS® (semaglutide) tablets 3mg, 7 mg or 14 mg is a prescription medicine used along with diet and exercise to improve blood sugar (glucose) in adults with type 2 diabetes.

• It is not known if RYBELSUS® can be used in people who have had pancreatitis
• RYBELSUS® is not for use in people with type 1 diabetes
• It is not known if RYBELSUS® is safe and effective for use in children under 18 years of age

• Key takeaways:

  • Rybelsus (semaglutide) is an oral medication approved to treat Type 2 diabetes. It contains the same active ingredient as Ozempic and Wegovy. Ozempic is approved for Type 2 diabetes, and Wegovy is approved for chronic weight management.

  • Rybelsus is currently being studied for weight loss in clinical trials. These studies involve higher doses than what’s currently approved and available for diabetes. 

  • Results show that an oral semaglutide (Rybelsus) dose of 50 mg results in similar weight loss as Wegovy. Due to these findings, Rybelsus’ manufacturer plans to request FDA approval in 2023. If approved for weight loss, it may be marketed under a different brand name.

RYBELSUS® (semaglutide) tablets 3mg, 7 mg or 14 mg is a prescription medicine used along with diet and exercise to improve blood sugar (glucose) in adults with type 2 diabetes.

• It is not known if RYBELSUS® can be used in people who have had pancreatitis
• RYBELSUS® is not for use in people with type 1 diabetes
• It is not known if RYBELSUS® is safe and effective for use in children under 18 years of age

• Key takeaways:

  • Rybelsus (semaglutide) is an oral medication approved to treat Type 2 diabetes. It contains the same active ingredient as Ozempic and Wegovy. Ozempic is approved for Type 2 diabetes, and Wegovy is approved for chronic weight management.

  • Rybelsus is currently being studied for weight loss in clinical trials. These studies involve higher doses than what’s currently approved and available for diabetes. 

  • Results show that an oral semaglutide (Rybelsus) dose of 50 mg results in similar weight loss as Wegovy. Due to these findings, Rybelsus’ manufacturer plans to request FDA approval in 2023. If approved for weight loss, it may be marketed under a different brand name.

Evolve Yohimbol contains Yohimbine Hydrochloride 5 mg per tablet. Yohimbine HCL is a well-known alkaloid compound commonly used in nutraceutical, wellness, and research-based formulations. The product is manufactured under controlled quality standards to ensure consistency and reliability.

Key Details:

• Active Ingredient: Yohimbine Hydrochloride

• Strength: 5 mg per tablet

• Dosage Form: Tablet

• Packaging: 100 Tabs

• Quality: Pharmaceutical-grade formulation